局部前列腺癌雄激素剥夺联合高剂量放疗后睾酮去势水平的预后价值:III期试验结果
DART01/05 III期试验纳入154例接受长期雄激素剥夺治疗(LTADT)联合高剂量放疗的局部前列腺癌患者,按睾酮最低值<20 ng/dL、中位值20-49 ng/dL、最高值≥50 ng/dL分层。10年bDFS、MFS、OS在<20与20-49 ng/dL亚组间无显著差异;中位睾酮≥50 ng/dL与bDFS下降显著相关(HR 6.58)。睾酮恢复时间与bDFS、MFS、OS无关。
要点
- 睾酮<20 ng/dL与20-49 ng/dL组10年bDFS、MFS、OS无显著差异。
- 中位睾酮≥50 ng/dL与bDFS显著下降相关(HR 6.58,95%CI 1.28-33.76,p=0.03)。
- ADT后睾酮恢复时间与bDFS、MFS、OS无显著相关。
核心结论
- 结果不支持将血清睾酮额外抑制至<20 ng/dL优于20-49 ng/dL的观点。
- ADT联合高剂量放疗后睾酮恢复时间不影响临床失败。
研究设计与样本
- DART01/05 III期随机试验纳入355例中高危局部前列腺癌患者,随机接受4个月ADT+高剂量放疗(STADT,N=178)或同方案后继续24个月ADT(LTADT,N=177)。
- 本分析纳入LTADT组中ADT期间至少3次睾酮检测的154例患者。
主要发现
- 按睾酮水平分为3亚组:最低值<20 ng/dL、中位值20-49 ng/dL、最高值≥50 ng/dL。
- 10年bDFS、MFS、OS在<20 ng/mL与20-49 ng/dL亚组间无统计学显著差异。
- 多因素分析显示中位睾酮≥50 ng/dL与bDFS下降显著相关(HR:6.58,95%CI 1.28-33.76,p=0.03)。
- ADT后睾酮恢复时间与bDFS、MFS、OS无相关性,且与任何睾酮亚组无显著关联。
关键数值与推荐
- 睾酮分层标准:最低值<20 ng/dL;中位值20-49 ng/dL;最高值≥50 ng/dL。
- 中位睾酮≥50 ng/dL与bDFS下降相关:HR 6.58(95%CI 1.28-33.76),p=0.03。
临床怎么用
- 局部前列腺癌ADT联合高剂量放疗期间,无需将睾酮额外抑制至<20 ng/dL以下。
- 应关注中位睾酮≥50 ng/dL的情况,其与生化疾病控制下降相关。
- 睾酮恢复时间不作为影响临床失败的预后因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVE: The optimal prognostic value of testosterone following androgen deprivation therapy (ADT) is controversial. We studied the effect of serum testosterone levels on clinical outcome in localized prostate cancer (PCa) treated with ADT and high-dose radiotherapy (HRT). PATIENTS AND METHODS: The DART01/05 trial randomized 355 men with intermediate and high-risk PCa to 4 months of ADT plus HRT (STADT, N = 178) or the same treatment followed by 24 months of ADT (LTADT, N = 177). This study included patients treated with LTADT who had at least 3 determinations of testosterone during ADT (N = 154). Patients were stratified into 3 subgroups by testosterone level: minimum <20 ng/dL; median 20-49 ng/dL; and maximum ≥50 ng/dL. Kaplan-Meyer and Cox regression analysis were used for overall survival (OS) and Fine & Gray regression model for metastasis free survival (MFS), biochemical disease-free survival (bDFS) and time to TT recovery. RESULTS: There were no statistically significant differences in 10-year bDFS, MFS, or OS between the <20 ng/mL and 20-49 ng/dL subgroups. Multivariate analysis showed that a median testosterone ≥50 ng/dL was significantly associated with a decrease in bDFS (HR: 6.58, 95%CI 1.28-33.76, p = 0.03). Time to testosterone recovery after ADT did not correlate with bDFS, MFS, or OS and was not significantly associated with any of the testosterone subgroups. CONCLUSIONS: Our results do not support the concept that additional serum testosterone suppression below 20 ng/dL is associated with better outcomes than 20-49 ng/dL. Time to testosterone recovery after ADT and HRT did not impact clinical failure.
引用
- Zapatero A, Álvarez A, Guerrero A, et al. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial. Radiother Oncol. 2021. PMID: 33964325. doi:10.1016/j.radonc.2021.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。